EGFR and neoplasm: Regarding the tumor micro-environment impact on the therapeutic effectiveness, several studies have shown that EGFR mutations can increase the proliferation of T-regulatory cells and myeloid-derived suppressor cells (MDSCs) [159], whereas they can also downregulate tumor-infiltrating lymphocytes (TILs) [160,161], tumor-associated macrophages (TAMs), immunoregulatory cytokines [162] and exosomes [163].